FDA

Latest News

NDA Resubmitted for Investigational Dry Eye Therapy, Reproxalap
NDA Resubmitted for Investigational Dry Eye Therapy, Reproxalap

June 17th 2025

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new data from an additional FDA-requested trial.

Timon-stock.adobe.com
Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

June 16th 2025

FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades

June 13th 2025

FDA Approves Ibtrozi For Adults With ROS1+ NSCLC
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC

June 12th 2025

FDA Approves Enflonsia To Protect Infants During Their First RSV Season
FDA Approves Enflonsia To Protect Infants During Their First RSV Season

June 12th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.